Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Financing Activities (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Cash from Financing Activities for 7 consecutive years, with -$2.2 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 100.46% to -$2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $359.3 million through Dec 2025, down 52.0% year-over-year, with the annual reading at $359.3 million for FY2025, 52.0% down from the prior year.
  • Cash from Financing Activities hit -$2.2 million in Q4 2025 for BridgeBio Pharma, down from -$894000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $547.9 million in Q1 2021 to a low of -$135.5 million in Q3 2021.
  • Historically, Cash from Financing Activities has averaged $114.1 million across 5 years, with a median of $1.1 million in 2022.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 4969.02% in 2021 and later skyrocketed 94005.62% in 2023.
  • Year by year, Cash from Financing Activities stood at $325.4 million in 2021, then crashed by 98.04% to $6.4 million in 2022, then tumbled by 170.93% to -$4.5 million in 2023, then skyrocketed by 10578.24% to $473.9 million in 2024, then tumbled by 100.46% to -$2.2 million in 2025.
  • Business Quant data shows Cash from Financing Activities for BBIO at -$2.2 million in Q4 2025, -$894000.0 in Q3 2025, and $302.0 million in Q2 2025.